Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03

Taverna Christian; Martinelli Giovanni; Hitz Felicitas; Mingrone Walter; Pabst Thomas; Cevreska Lidija; del Giglio Auro; Vanazzi Anna; Laszlo Daniele; Raats Johann; Rauch Daniel; Vorobiof Daniel A.; Lohri Andreas; Rudolf Christine Biaggi; Rondeau Stephanie; Rusterholz Corinne; Heijnen Ingmar A. F. M.; Zucca Emanuele; Ghielmini Michele

首页> 外文期刊>Journal of Clinical Oncology >Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03

【24h】

Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03

机译：单剂利妥昔单抗诱导滤泡性淋巴瘤后利妥昔单抗维持最多5年：随机对照III期SAKK 35/03试验的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2016年第5期|共9页
作者
Taverna Christian; Martinelli Giovanni; Hitz Felicitas; Mingrone Walter; Pabst Thomas; Cevreska Lidija; del Giglio Auro; Vanazzi Anna; Laszlo Daniele; Raats Johann; Rauch Daniel; Vorobiof Daniel A.; Lohri Andreas; Rudolf Christine Biaggi; Rondeau Stephanie; Rusterholz Corinne; Heijnen Ingmar A. F. M.; Zucca Emanuele; Ghielmini Michele;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03 [J] . Taverna Christian, Martinelli Giovanni, Hitz Felicitas, Journal of Clinical Oncology . 2016,第5期

机译：单剂利妥昔单抗诱导滤泡性淋巴瘤后利妥昔单抗维持最多5年：随机对照III期SAKK 35/03试验的结果
2. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03 [J] . Taverna Christian, Martinelli Giovanni, Hitz Felicitas, Journal of Clinical Oncology . 2016,第5期

机译：Rituximab在卵泡淋巴瘤中单药rituximab诱导后最多5年的维持：随机控制第III阶段试验SAKK 35/03的结果
3. Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03 [J] . Taverna Christian, Martinelli Giovanni, Hitz Felicitas, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：Rituximab维持治疗在滤泡淋巴瘤最多5年：随机阶段III试验SAKK 35/03的最终结果
4. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03 [O] . Christian Taverna, Giovanni Martinelli, Felicitas Hitz, -1

机译：单剂利妥昔单抗诱导滤泡性淋巴瘤后利妥昔单抗维持最多5年：随机对照III期试验SAKK 35/03的结果
5. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. [O] . Taverna, Christian, Martinelli, Giovanni, Hitz, Felicitas, 2016

机译：单剂利妥昔单抗诱导滤泡性淋巴瘤后，利妥昔单抗维持最多5年：随机对照III期SAKK 35/03试验的结果。

Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03

摘要

著录项

相似文献

相关主题

期刊订阅